The Negative Predictive Value of Electrical Impedance Scanning in BI-RADS Category IV Breast Lesions

Abstract

With a NPV of 97.1% of EIS in BI-RADS category IV breast lesions, a negative result in these lesions could be firm indication to manage them as BI-RADS-category III and refer patients for a 6-month short-interval follow-up rather than performing a biopsy. The best adjunctive diagnostic performance can be achieved by a combination of US and EIS. Costs and patient morbidity could be minimized.

Electrical impedance scanning as a new breast cancer risk stratification tool for young women

“…Inclusion of women age 40-45 undergoing annual screening mammography also permitted an assessment of sensitivity in non-palpable lesions since at the age range of 30-39 years women with non-palpable findings are rarely biopsied. In fact, T-Scan sensitivity was increased in smaller lesions, which is consistent with previously published reports [17][18][19][20]. Not only are EIS characteristics independent of patient age in the pre-menopausal breast, but also importantly, T-Scan specificity and sensitivity in this study were found to be independent of breast lesion palpability.…”

“…Similarly, even for the lower bound of the 95% confidence interval of the estimated sensitivity (17.4%), the relative probability significantly exceeded the study success criterion of 2.0 (Pr ¼ 3.27). In fact, T-Scan sensitivity was increased in smaller lesions, consistent with previously published reports [17,18,20]. Importantly, T-Scan specificity and sensitivity were found to be independent of breast lesion palpability on CBE.…”

“…The evaluated technology, electrical impedance scanning (EIS), measures tissue-specific impedance changes across each breast to identify impedance patterns that may be associated with cancer risk [17][18][19][20]. This study used the T-Scan TM ED2000 (Mirabel Medical Systems, Austin, TX) to evaluate the use of EIS for breast cancer risk assessment in 1,103 women.…”

Prospective study of electrical impedance scanning for identifying young women at risk for breast cancer

“…Despite wide-ranging experimental work and technological development, only recently have high-speed software processing platforms made possible clinically useful EIS cancer detection systems. A significant body of data published recently supports the potential for differences in the bioelectrical signature of malignant and benign/normal tissues to be used in cancer detection including melanoma, malignant lymph nodes, thyroid and breast cancer [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40].…”

Comparison of Three Kinds of Electrode–Skin Interfaces for Electrical Impedance Scanning

“…6,[16][17][18]23,24,27,28,30 At present, the EIS system applied in clinical practice is TransScan TS 2000, which was approved by the U.S. FDA for diagnostic use on breast lesions in 1999. It was later developed into the T-Scan 2000ED.…”